Skip to main content

Novo Nordisk Settles Lawsuits Over Copycat Versions of Ozempic, Wegovy

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 12, 2024.

By Carole Tanzer Miller HealthDay Reporter

MONDAY, Feb. 12, 2024 — Novo Nordisk has settled lawsuits against two Florida businesses that claimed to sell copycat versions of its popular weight-loss drugs Ozempic and Wegovy.

The Danish drugmaker announced the settlements Friday, according to NBC News.

The move capped a legal battle that began in late November when the company filed 12 lawsuits against clinics, medical spas and compounding pharmacies in the United States that claimed to offer semaglutide, the active ingredient in Ozempic and Wegovy.

Novo Nordisk, which holds the patent on semaglutide, does not supply the ingredient to outside groups, NBC News noted. Semaglutide is used to treat type 2 diabetes and is a popular, injectable weight-loss drug.

With the settlements announced last week, Florida-based Cosmetic Laser Professionals Med Spa and Nuvida Rx Weight Loss are permanently barred from claiming that their compounded drugs have approval from the U.S. Food and Drug Administration, Novo Nordisk said.

They are also forbidden from "misleading" advertising and using any Novo Nordisk trademarks or logos in their products.

The settlement gives both companies a year to make the necessary changes.

Compounded drugs are custom-made. Ingredients are combined, mixed or altered for an individual patient.

While these drugs are not FDA-approved, they are often sought when approved medications are in short supply. As use of semaglutide for weight control has soared, many patients with diabetes who depend on it to control their blood sugar as well as those seeking to slim down have had trouble getting their prescriptions filled.

Novo Nordisk said late last year that it had tested compounded products allegedly being sold by two Florida pharmacies. It said 33% of one sample was "unknown impurities." Another sample was also impure and contained lower levels of the active ingredient than described, according to a separate lawsuit.

Sources

  • NBC News

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

Read this next

It's Safe to Take GLP-1 Weight Loss Meds Before Surgery: Study

THURSDAY, June 6, 2024 -- Despite recent concerns that taking Ozempic, Wegovy or other GLP-1 medications might be unsafe before a surgery, a new review has uncovered no such...

Wegovy, Ozempic May Help Curb Alcohol Dependence

TUESDAY, June 4, 2024 -- Could the blockbuster GLP-1 meds like Wegovy and Ozempic have a role to play in helping people cut down on problem drinking? A new study suggests...

Could New Weight-Loss Drugs Be Changing Women's Taste for Sweets?

MONDAY, June 3, 2024 -- Ozempic and Wegovy appear to improve people’s sensitivity to tastes, potentially lowering their desire for sweets, a new study suggests. The active...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.